Default company panoramic image
Logo

HepatoChem

HepatoChem develops chemistry based tools for life sciences. We have developed and currently sell our products.

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Beverly, MA, USA
  • Currency USD
  • Founded August 2008
  • Employees 5
  • Incorporation Type C-corp
  • Website hepatochem.com

Company Summary

HepatoChem owns a technology platform used to design chemical catalyst based kits for life sciences researchers. Chemical kits containing reagents in appropriate amounts for pre-selected conditions known to be successful for specific chemical reaction would eliminate the barrier to entry, cutting costs, reagents and time. These kits may have the same impact in accelerating drug discovery that molecular biology kits had in biological research.

Team

  • Default avatar
    Nick Terrett
    Advisory board member

    Nick is currently CSO at Ensemble Therapeutics, a role he has held since May of 2006. Nick has a PhD in chemistry from the University of Cambridge, and has extensive experience as a medicinal chemist for Glaxo and for Pfizer in England and in the US. He worked initially in cardiovascular disease, before leading the chemistry team on cGMP PDE inhibitors for angina and erectile dysfunction, and is an inventor on patents for Viagra® and Revatio®.

  • Default avatar
    Marc Bazin
    President

    Marc Bazin has worked in the pharmaceutical industry for over 15 years. His expertise includes organic synthesis, biomimetic catalysis and automation. Prior to founding HepatoChem in 2008, he was a senior scientist at Pfizer, Cambridge, MA and France. He was also employed by Servier Research institute from 1995-2003. He holds an MS in organic chemistry from the CNAM, France and has held a visiting scientist position at Princeton University.

  • Default avatar
    Jean-Marie Vallet
    Board director

    Dr. Vallet has over 20 years experience in a variety of research, marketing and business roles in life sciences, including in 14 years the pharmaceutical industry. In 2000, he founded Cyrma, a consulting company. Dr. Vallet joined EnVivo in June 2006 and served as Vice President of Business and Commercial Development at Guilford Pharm., Inc. He has held senior level corporate positions at Pierre Fabre, Parke-Davis, Warner Lambert and BMS.

  • Default avatar
    Thierry Bernard
    Advisory board member

    Mr. Thierry Bernard serves at bioMerieux SA as Member of the Management Committee and Director for Global Commercial Operations. He joined the Company in 1999, then in 2002, he assumed responsibility for the Europe, Middle East and Africa zone. Mr. Bernard is a graduate of Institut d’Etudes Politiques de Paris and holds a MS in Economics and Business Administration from Europe College, a MS degree from the London School of Economics.

  • Default avatar
    Ryan Buzdygon
    Director

    Dr. Ryan Buzdygon’s research background is focused on the exploitation of organometallic reaction mechanisms to influence chemical transformations. He received his Ph.D. from Princeton University where he worked under Professor John Groves. His research on synthetic metalloporphyrins as mimics for Cytochrome P450 activity, demonstrated the utility of these catalysts for bio-transformations producing the metabolites of drug compounds.

  • Default avatar
    Marie Landel
    CFO

    Marie is a French CPA and she holds an MBA from the European Business School (Paris, Frankfurt, London). She worked both as inside counsel for companies and as part of a CPA practice in France before starting her own practice in the US in 1989. She was the President of the French-American Chamber of Commerce for three years and is currently an active member of the New England trade adviser group to the French government.

Advisors

  • Default avatar
    Foley & Lardner
    Lawyer
    Unconfirmed
    Default avatar
    Jim Elgart
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Heartland Bridge Capital
    Unconfirmed
    Default avatar
    Private investors
    Unconfirmed